AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

被引:4
|
作者
Ozga, Michael [1 ]
Zhao, Qiuhong [1 ]
Benson, Don [1 ]
Elder, Patrick [1 ]
Williams, Nita [1 ]
Bumma, Naresh [1 ]
Rosko, Ashley [1 ]
Chaudhry, Maria [1 ]
Khan, Abdullah [1 ]
Devarakonda, Srinivas [1 ]
Kahwash, Rami [2 ]
Vallakati, Ajay [2 ]
Campbell, Courtney [2 ]
Parikh, Samir V. [3 ]
Almaani, Salem [3 ]
Prosek, Jason [3 ]
Bittengle, Jordan [1 ]
Pfund, Katherine [1 ]
LoRusso, Samantha [4 ]
Freimer, Miriam [4 ]
Redder, Elyse [5 ]
Efebera, Yvonne [1 ]
Sharma, Nidhi [1 ]
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Internal Med, Div Cardiol, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Div Nephrol, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA
[5] Ohio State Univ, Dept Oncol Rehabil, Columbus, OH 43210 USA
关键词
AL amyloidosis; transplantation; maintenance therapy; fluorescent in situ hybridization; plasma cell burden; LIGHT-CHAIN AMYLOIDOSIS; STAGING SYSTEM; MELPHALAN; RESPONSES; MYELOMA;
D O I
10.3390/jcm9113778
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Autologous stem cell transplantation (ASCT) remains an effective treatment option for many patients with systemic light chain (AL) amyloidosis. While maintenance post ASCT in multiple myeloma is now standard, the decision to utilize maintenance in AL amyloidosis remains largely unexplored. The present study aims to determine the prognostic significance of utilizing maintenance therapy following ASCT and assess the impact of fluorescent in situ hybridization (FISH) abnormalities, bone marrow plasma cell burden (BMPC), and degree of organ involvement on this decision. Methods and results: This is a retrospective analysis of fifty AL amyloidosis patients who underwent ASCT at The Ohio State University. Twenty-eight patients received maintenance and twenty-two did not. Kaplan-Meier survival analysis was used to compare the effect of maintenance therapy with no significant difference in PFS (p = 0.66) and OS (p = 0.32) between the two groups. There was no difference in survival based on maintenance when further categorized by FISH, PFS (p = 0.15), and OS (p = 0.65); BMPC >= 10%, PFS (p = 0.49), and OS (p = 0.32); or with 2 or more organs involved, PFS (p = 0.34) and OS (p = 0.80). Conclusion: Maintenance therapy post ASCT did not impact PFS or OS when categorized by FISH abnormalities, increasing BMPC, or >= 2 organs involved in AL amyloidosis patients.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [1] AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
    Ozga, Michael
    Zhao, Qiuhong
    Benson, Don M., Jr.
    Elder, Patrick
    Williams, Nita
    Bumma, Naresh
    Rosko, Ashley E.
    Chaudhry, Maria
    Khan, Abdullah Mohammad
    Devarakonda, Srinivas
    Kahwash, Rami
    Vallakati, Ajay
    Campbell, Courtney
    Parikh, Samir
    Almaani, Salem
    Prosek, Jason
    Redder, Elyse
    Efebera, Yvonne A.
    Sharma, Nidhi
    [J]. BLOOD, 2019, 134
  • [2] Autologous stem cell transplantation for AL amyloidosis: a standard therapy?
    P Moreau
    [J]. Leukemia, 1999, 13 : 1929 - 1931
  • [3] Autologous stem cell transplantation for AL amyloidosis: a standard therapy?
    Moreau, P
    [J]. LEUKEMIA, 1999, 13 (12) : 1929 - 1931
  • [4] AUTOLOGOUS STEM-CELL TRANSPLANTATION IN AMYLOIDOSIS AL
    MAJOLINO, I
    MARCENO, R
    PECORARO, G
    SCIME, R
    VASTA, S
    LIBERTI, G
    RIZZO, A
    INDOVINA, A
    CARONIA, F
    [J]. BONE MARROW TRANSPLANTATION, 1993, 11 (01) : 85 - 85
  • [5] Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation
    Dimopoulos, Meletios A.
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (06) : 963 - 964
  • [6] Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy
    Nelson, Blessie Elizabeth
    Ramdial, Jeremy L.
    Bashir, Qaiser
    Saini, Neeraj
    Hosing, Chitra
    Popat, Uday R.
    Delgado, Ruby
    Lee, Hans C.
    Kaufman, Gregory P.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    Srour, Samer A.
    [J]. BLOOD, 2021, 138
  • [7] Autologous stem cell transplantation and maintenance therapy
    Moreau, Philippe
    [J]. HEMATOLOGICAL ONCOLOGY, 2013, 31 : 42 - 46
  • [8] Autologous stem cell transplantation following heart transplantation for AL amyloidosis
    Ripamonti, F.
    Fiaccadori, V.
    Rossi, M.
    Pochintesta, L.
    Bernasconi, P.
    Caldera, D.
    Colombo, A. A.
    Troletti, D.
    Pellegrini, C.
    Palladini, G.
    Merlini, G.
    Vigano, M.
    Alessandrino, E. P.
    [J]. BONE MARROW TRANSPLANTATION, 2011, 46 : S262 - S262
  • [9] Deferred autologous stem cell transplantation in systemic AL amyloidosis
    Richa Manwani
    Ute Hegenbart
    Shameem Mahmood
    Sajitha Sachchithanantham
    Charalampia Kyriakou
    Kwee Yong
    Rakesh Popat
    Neil Rabin
    Carol Whelan
    Tobias Dittrich
    Christoph Kimmich
    Philip Hawkins
    Stefan Schönland
    Ashutosh Wechalekar
    [J]. Blood Cancer Journal, 8
  • [10] Outcome of autologous stem cell transplantation for AL amyloidosis in the UK
    Goodman, Hugh J. B.
    Gillmore, Julian D.
    Lachmann, Helen J.
    Wechalekar, Ashutosh D.
    Bradwell, Arthur R.
    Hawkins, Philip N.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (04) : 417 - 425